Explore our resources by research/diagnostic specialty or content type
ALPCO specialists are leveraging their extensive expertise to create a growing collection of resources for your research and testing. Find resources that benefit your work using the handy filters.
Discover how primary care providers, emergency clinicians, advanced care practitioners (ACPs), and other healthcare professionals can play a pivotal role in the early diagnosis and management of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.
Lactoferrin is a key member of the transferrin family of proteins that protects against microbial infection, regulates iron absorption, and modulates immune function in a wide range of tissues. The Lactoferrin CLIA Kit is a chemiluminescence immunoassay for the quantitative determination of lactoferrin in human stool samples using the KleeYa automated platform.
This infographic distills the essence of the new American Gastroenterological Association (AGA) Clinical Practice Guideline on the Role of Biomarkers in Crohn's Disease (CD). It sheds light on the nuanced recommendations for using biomarkers to monitor and evaluate CD, emphasizing their value in conjunction with clinical symptoms.
ALPCO’s automated turbidimetric solution for calprotectin testing offers enhanced efficiency without compromising clinical sensitivity or specificity. Clinicians can prioritize endoscopic evaluation for the patients that need it most and quickly put IBS patients on the right treatment path.
Join our speaker from Department of Pathology , University of Utah School of Medicine, Dr. Heather Nelson, to discuss how to validate and launch a FDA-approved assay.
ALPCO offers targeted GI solutions suitable for all types of labs. Our offerings range from plate-based to clinical chemistry analyzer-based and automated flash chemiluminescence solutions, all designed to accommodate your lab’s expanding testing needs and capabilities.
In the webinar, Dr. Benjamin Click from the University of Colorado, Department of Gastroenterology, underscores the critical role of non-invasive monitoring methods, particularly fecal calprotectin monitoring, in guiding treatment adjustments and achieving therapeutic goals..
In an effort to improve patient care, an increasing number of gastroenterologists are using fecal calprotectin levels as a first step in the diagnosis of IBD versus IBS. ALPCO tests enable clinicians to accurately assess patients via calprotectin and quickly start patients on the right treatment path.
Reduce False Positives from 26% to 7%! An increase in clinical specificity, and a decrease in false positives, enables clinicians to better evaluate IBD/IBS patients. Clinicians can schedule follow-up colonoscopies for the patients that need it most and start IBS patients on the right treatment path.
